NCT05826964 2026-01-13
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
Phase 2 Active not recruiting
Clinical Trials
9 trialsNCT04762979 2026-01-02
Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer
Big Ten Cancer Research Consortium
Phase 2 Active not recruiting
NCT06495164 2025-11-25
A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer
Pfizer
Active not recruiting
NCT03959891 2025-09-29
AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)
Massachusetts General Hospital
Phase 1 Active not recruiting
NCT04188548 2025-06-04
EMBER
Eli Lilly and Company
Phase 1 Active not recruiting
NCT03917082 2023-06-15
LALEAST
British Columbia Cancer Agency
Phase 2 Active not recruiting
NCT02603679 2021-08-03
PREDIX LumB
Karolinska University Hospital
Phase 2 Active not recruiting
NCT02592083 2020-07-07
PREDIX LumA
Karolinska University Hospital
Phase 2 Active not recruiting
NCT02338310 2020-02-17
POETIC
Institute of Cancer Research, United Kingdom
Phase 3 Active not recruiting